Effects of Immunoglobulin upon Murine Myocarditis Caused by Influenza A Virus: Superiority of Intact Type to F(ab′)2 Type

Journal of Cardiovascular Pharmacology

Volumn 43, Issue 1, 2004, Pages 61-67

  Kishimoto, Chiharu ^a,b   Hiraoka, Yuji ^a   Takada, Hitoshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Immunoglobulin; Influenza virus; Myocarditis

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; INFLUENZA VIRUS A; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STRAIN DIFFERENCE; SURVIVAL RATE; VIRUS MYOCARDITIS;

ANIMALS; ANTIVIRAL AGENTS; GAMMA-GLOBULINS; IMMUNOGLOBULINS; INFLUENZA A VIRUS; MALE; MICE; MYOCARDITIS; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 0346963013     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200401000-00010     Document Type: Article

References (22)

1. Woodruff JF. Viral myocarditis: a review. Am J Pathol. 1980;101:427-484.
2. Reyes M, Lerner AM. Coxsackievirus myocarditis: with special reference to acute and chronic effects. Prog Cardiovasc Dis. 1985;27:373-394.
3. Finland M, Parker JrF, Bames MW, et al. Acute myocarditis in influenza A infections: Two cases of nonbacterial myocarditis, with isolation of virus from the lungs. Am J Med Sci. 1945;209:455-468.
4. Engblom E, Ekfors TO, Meurman OH, et al. Fatal influenza A myocarditis with isolation of virus from the myocardium. Acta Med Scand. 1983;213:75-78.
5. Takada H, Kishimoto C, Hiraoka Y. Therapy with immunoglobulin suppresses myocarditis in a murine coxsackievirus B3 model: antiviral and anti-inflammatory effects. Circulation. 1995;92:1604-1611.
6. Drucker NA, Colan SD, Lewis AB, et al. γ-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89:252-257.
7. McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocardilis and acute cardiomyopathy. Circulation. 1997;95:2476-2478.
8. McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254-2259.
9. Ochiai H, Ikesue A, Kurokawa M, et al. Enhanced production of rat interleukin-8 by in vitro and in vivo infections with influenza A NWS virus. J Virol. 1993;67:6811-6814.
10. Sakai S, Kawamata H, Mantani N, et al. Therapeutic effect of antimacrophage inflammatory protein 2 antibody on influenza virus-induced pneumonia in mice. J Virol. 2000;74:2472-2476.
11. Ochiai H, Sakai S, Kogure T, et al. Development and some applications of enzyme linked immunosorbent assay system for murine macrophage inflammatory protein-2 (MIP-2). Mediat Inflamm. 1996;5:206-209.
12. Wolf HM, Eible MM. Immunomodulatory effect of immunoglobulins. Clin Exp Rheum. 1996;14(Suppl 15):S17-S25.
13. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999;340:227-228.
14. Kishimoto C, Takamatsu N, Kawamata H, et al. Immunoglobulin treatment ameliorates murine myocarditis associated with reduction of neurohumoral activity and improvement of extracellular matrix change. J Am Coll Cardiol. 2000;36:1979-1984.
15. Yue TL, Wang X, Sung CP, et al. Interleukin-8: a mitogen and chemoattractant for vascular smooth muscle cells. Circ Res. 1994;76:1-7.
16. Taub DD, Anver M, Oppenheim JJ, et al. T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes. J Clin Invest. 1996;97:1931-1941.
17. Feng L, Xia Y, Yoshimura T, et al. Modulation of neutrophil influx in glomerulonephritis in the rat with anti-macrophage inflammatory protein-2 (MIP-2) antibody. J Clin Invest. 1995;95:1009-1017.
18. Cook DN, Beck MA, Coffman TM, et al. Requirement of MIP-1α for an inflammatory response to viral infection. Science. 1995;269:1583-1585.
19. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.
20. Shioji K, Kishimoto C, Sasayama S. Fc receptor-mediated inhibitory effect of immunoglobulin therapy on autoimmune giant cell myocarditis: concomitant suppression of the expression of dendritic cells. Circ Res. 2001;89:540-546.
21. Nemes E, Teichman F, Roos D, et al. Activation of human granulocytes by intravenous immunoglobulin preparations is mediated by FcγRIII and FcγRIII receptors. Pediatr Res. 2000;47:357-361.
22. Jodo S, Hohlbaum AM, Xiao S, et al. CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-mediated enhancement of cytotoxicity. J Immunol. 2000;165:5487-5494.